Brugada Syndrome: Comprehensive Research Report

1. Disease Overview and Identifiers

Brugada syndrome (BrS) is an inherited primary electrical disease of the heart characterized by a distinctive coved (type 1) ST-segment elevation in the right precordial leads (V1–V3) on a 12-lead electrocardiogram (ECG), occurring in the absence of structural heart disease, and associated with an increased risk of polymorphic ventricular tachycardia, ventricular fibrillation (VF), and sudden cardiac death (SCD), typically during sleep or at rest (GeneReviews — Brugada Syndrome, NCBI Bookshelf; MedlinePlus Genetics). It was first described as a distinct clinical entity by Pedro and Josep Brugada in 1992.

Key identifiers: - OMIM: #601144 (BRGDA1) plus multiple additional locus entries (BRGDA2–BRGDA9+) corresponding to different causal/susceptibility genes (OMIM #601144) - MONDO: MONDO:0015263 - Orphanet: ORPHA:130 - ICD-10-CM: I49.8 (other specified cardiac arrhythmias) — no dedicated Brugada-specific code - ICD-11: BC9Z / related channelopathy codes - MeSH: D053840 (Brugada Syndrome)

Synonyms: Brugada syndrome; BrS; sudden unexplained nocturnal death syndrome (SUNDS, historically linked, particularly in Southeast Asian populations); Pokkuri death syndrome (Japan); right bundle branch block, persistent ST elevation, and sudden death syndrome.

Most published data derive from aggregated disease-level resources (case series, registries such as BRAVO, SADS-TW, FINGER, PRELUDE, and large single- and multi-center cohorts) rather than a single unified EHR-based population; recent large ECG-based population studies (e.g., a 2024 Mayo Clinic 30-year retrospective of >5.3 million ECGs) provide the closest approximation to real-world, individual-level ascertainment (Prevalence and Incidence of Type 1 Brugada Pattern: A 30-Year Experience at Mayo Clinic, 2024).

2. Etiology

2.1 Genetic Causal Factors

BrS is genetically heterogeneous. Although more than 20–23 genes have been reported in association studies, SCN5A (encoding the cardiac sodium channel α-subunit Nav1.5) remains the only gene with robust, clinically actionable evidence for causality, per ClinGen and expert consensus reviews (Annual Review of Genomics and Human Genetics — The Genetics of Brugada Syndrome). SCN5A loss-of-function (LOF) variants are found in roughly 20–25% of clinically diagnosed BrS patients (Cureus 2024; GeneReviews).

Other genes historically implicated but with weaker or now-disputed evidence include: - SCN1B, SCN3B (sodium channel β-subunits) - CACNA1C, CACNB2, CACNA2D1 (L-type calcium channel subunits — associated with a mixed Brugada/short-QT phenotype) - KCNE3, KCNJ8, KCND3 (potassium channel components affecting Ito) - GPD1L, HCN4, RANGRF, SLMAP, TRPM4, PKP2

A large 2023–2025 gene-curation reappraisal by ClinGen substantially deflated the historical "23-gene panel" — most minor genes lack sufficient case-control or functional replication to be considered disease-causing, leaving SCN5A as the sole "definitive" gene (European Journal of Human Genetics 2025).

2.2 Risk Factors

Genetic risk factors: - SCN5A pathogenic LOF variants (missense, nonsense, frameshift, splice-site) causing reduced peak sodium current (INa) - Common susceptibility SNPs at SCN5A-SCN10A (rs11708996, rs10428132) and near HEY2 (rs9388451) — first identified in a 2013 GWAS (Nature Genetics 2013; PubMed 23872634) - A 2022 expanded GWAS meta-analysis of 2,820 BrS cases and 10,001 controls identified 21 association signals at 12 loci (10 novel), with strong SNP-heritability estimates supporting a substantially polygenic architecture layered on top of monogenic SCN5A disease (SADS.org — 2022 Nature Genetics GWAS) - Male sex (prevalence 8–10-fold higher in men than women, attributed in part to greater Ito current density in men, androgen effects, and possibly differential Nav1.5 expression) - Family history of BrS or unexplained sudden death, particularly at a young age

Environmental/acquired risk factors: - Fever — the single most important acute trigger; fever-induced episodes occur in an estimated 20–30% of diagnosed BrS patients, and first clinical manifestation frequently occurs during a febrile illness, especially in children (search synthesis of clinical literature) - Sodium-channel-blocking drugs (Class IA/IC antiarrhythmics, tricyclic antidepressants, some anesthetics/local anesthetics, cocaine) - Excessive alcohol intake, cannabis use - Electrolyte disturbances (hyperkalemia, hypokalemia) - Vagotonic states, bradycardia (sleep, post-prandial states — explaining the classic nocturnal timing of events)

2.3 Protective Factors

Limited literature exists on protective genetic/environmental factors specific to BrS. Gain-of-function polymorphisms increasing INa density and lower Ito expression (relevant to the sex disparity) are inferentially protective; no dedicated protective-variant catalogue analogous to those for coronary disease exists. Avoidance of triggering drugs and prompt fever control are the primary modifiable "protective" behavioral measures (BrugadaDrugs.org).

2.4 Gene-Environment Interactions

The clearest gene-environment interaction is the fever-Nav1.5 relationship: temperature-dependent destabilization of mutant Nav1.5 channel gating/inactivation kinetics (particularly for certain trafficking-defective or fast-inactivating SCN5A variants) unmasks or exacerbates the type 1 ECG pattern and arrhythmic risk during febrile states — "fever worsens sodium channel dysfunction by further reducing conductance" (search synthesis). Drug-gene interactions are similarly central: sodium-channel-blocking agents unmask latent BrS in genetically susceptible individuals via pharmacologic provocation testing (ajmaline, flecainide, procainamide, pilsicainide), which is diagnostically exploited but also constitutes a real-world risk when such drugs are prescribed inadvertently.

3. Phenotypes

3.1 Clinical Signs / Electrocardiographic Phenotype

Type 1 Brugada ECG pattern (the only diagnostic pattern): coved ST-segment elevation ≥2 mm in ≥1 right precordial lead (V1–V2, standard or superior intercostal placement), followed by a negative T wave, occurring spontaneously or after sodium-channel blocker provocation. HPO: consider HP:0025145 (or general "abnormal ST segment"/ECG abnormality terms; BrS lacks a fully specific HPO leaf term for the type-1 coved pattern — bind to the most specific reachable descriptor).
Type 2/3 (saddleback) patterns — non-diagnostic on their own; require provocation testing.
Syncope (HP:0001279) — often due to self-terminating polymorphic VT.
Nocturnal agonal respiration — a classical historical description in SUNDS-overlap cases.
Sudden cardiac death / aborted cardiac arrest (HP:0001645-adjacent / cardiac arrest terms) — may be the first presentation in up to 1/3 of cases.
Palpitations (HP:0001962).
Atrial fibrillation — supraventricular arrhythmia comorbidity reported in ~10–20% of BrS cohorts.
Conduction abnormalities: first-degree AV block, right bundle branch block-like QRS morphology, HV interval prolongation on electrophysiology study.

3.2 Phenotype Characteristics

Age of onset: Typically manifests in adulthood, mean age of sudden death/arrhythmic event in the 3rd–4th decade of life (often cited ~40 years); pediatric presentations occur, usually fever-triggered.
Severity/frequency: Highly variable expressivity — from asymptomatic ECG pattern carriers (common, especially among family members of probands) to malignant, recurrent VF/sudden death.
Progression: Episodic — ECG pattern can be concealed at baseline and unmasked only during fever, drug challenge, or vagotonic states ("dynamic" pattern).
Sex disparity: Prevalence and symptomatic expression are 8- to 10-fold higher in males than females.
Circadian pattern: Arrhythmic events cluster during sleep/nocturnal hours and periods of vagal predominance.

3.3 Quality of Life Impact

Recurrent ICD shocks (appropriate and inappropriate) are a major quality-of-life burden and psychological stressor in BrS cohorts, driving interest in alternative therapies such as quinidine and catheter ablation to reduce shock burden — one driver of the 2023–2024 shift toward epicardial substrate ablation research (BRAVO Registry, Circulation 2023).

4. Genetic/Molecular Information

4.1 Causal Gene

SCN5A (HGNC:10593; chromosome 3p22.2) encoding Nav1.5, the pore-forming α-subunit of the cardiac voltage-gated sodium channel. LOF variants are found in ~20–25% of clinically diagnosed patients (Karger MPP 2024 review).

4.2 Variant Classification and Functional Consequences

Variant types: missense (most common), nonsense, frameshift, splice-site, and occasionally large deletions.
Functional consequence: predominantly loss of function — reduced peak INa via decreased channel trafficking to the membrane, accelerated inactivation, delayed recovery from inactivation, or reduced single-channel conductance.
A 2024–2025 systematic review/meta-analysis (17 studies, 3,568 BrS patients, 3,030 genotyped) confirmed that LOF-type SCN5A variants (versus non-LOF or normal-function variants) are associated with worse arrhythmic prognosis, though the discriminative power is described as only "weak-to-moderate," insufficient for standalone risk stratification (SCN5A variant type-dependent risk prediction in Brugada syndrome, PMC 2025; ResearchGate meta-analysis 2024).
ACMG/ClinVar classification varies widely by variant; functional electrophysiological studies (patch-clamp, heterologous expression) are frequently required to adjudicate variants of uncertain significance (VUS).

4.3 Common/Susceptibility Variants (Polygenic Component)

rs11708996 (SCN5A intronic), rs10428132 (SCN10A), rs9388451 (near HEY2) — the three GWAS-validated common risk SNPs from the original 2013 discovery cohort, combined into a BrS polygenic risk score (BrS-PRS) — likelihood of BrS increases consistently with increasing risk-allele count (Circulation: Genomic and Precision Medicine, SADS-TW validation, PMC; PubMed 32490690).
The expanded 2022 GWAS (2,820 cases/10,001 controls) found 21 signals across 12 loci, and demonstrated that in 2,182 unrelated BrS patients, higher PRS was independently associated with a significantly greater risk of a first life-threatening arrhythmic event since birth — supporting reconceptualization of BrS as a partly polygenic, SCN5A-independent-susceptibility disease (search synthesis, 2022 Nature Genetics).

4.4 Modifier/Regulatory Genes

HEY2 — a Notch-pathway bHLH transcription factor specifically expressed in developing ventricular myocardium; indispensable for ventricular myocyte differentiation, chamber identity, and cardiac morphogenesis. GWAS association with BrS implicates altered transcriptional regulation of ion-channel gene expression during cardiac development, rather than a structural channel defect per se.
SCN10A encodes Nav1.8, historically considered a neuronal channel, but shown to modestly contribute to cardiac INa; LOF SCN10A variants reduce cardiac sodium current.
Established transcriptional regulators of Nav1.5/ion-channel expression relevant to BrS susceptibility: HEY2, TBX20, GATA4, TBX5, IRX3/IRX5.
WT1 — a 2025 preprint identified WT1 as impacting SCN5A expression and cardiac conduction, a novel candidate modifier (bioRxiv 2025).
A rare non-coding enhancer variant in SCN5A was described (medRxiv, 2023) contributing to unusually high BrS prevalence in Thailand — a population-specific regulatory mechanism (medRxiv 2023).

4.5 Epigenetics

Dedicated epigenetic (DNA methylation/histone) studies specific to BrS are sparse in the literature relative to other cardiomyopathies; the primary "epigenetic-adjacent" finding is the transcriptional-regulation angle via HEY2/GATA4/TBX5, i.e., altered developmental gene-regulatory programming of ion channel expression rather than classical postnatal epigenetic marks.

4.6 Chromosomal Abnormalities

BrS is not typically associated with large structural chromosomal rearrangements; it is a channelopathy driven by point variants/small indels in ion channel and channel-regulatory genes, not copy-number disorders.

5. Environmental Information (Triggers and Phenocopy Causes)

5.1 True Trigger Factors (in genetically susceptible individuals)

Fever/febrile illness — the dominant modifiable trigger (see §2.4). Recommended: "12-lead ECG is strongly recommended even in a low-grade fever state in patients belonging to a high-risk group" (search synthesis).
Sodium-channel-blocking drugs across classes: Class IA (ajmaline, procainamide, disopyramide), Class IC (flecainide, propafenone, pilsicainide), tricyclic/tetracyclic antidepressants, some anesthetics/local anesthetics, lithium, and certain anticonvulsants (e.g., lacosamide, implicated in at least one case report during septicemia — PMC 2021).
Cocaine, cannabis, excessive alcohol intake.
Vagotonic states (rest, sleep, the post-prandial period) — mechanistically linked to the nocturnal predominance of events.
Electrolyte disturbances (hyperkalemia).

5.2 Brugada Phenocopy — Reversible, Non-Congenital Mimics

Distinct from true BrS, "Brugada phenocopy" describes reversible Brugada-pattern ECGs arising from an acute, identifiable, non-genetic cause, with normalization once the underlying condition resolves (World Journal of Cardiology 2014, PMC). Documented causes include: - Electrolyte abnormalities (notably hyponatremia — case report/review, PMC 2025: Brugada Phenocopy due to Hyponatremia; also hyperkalemia) - Pulmonary embolism (right ventricular strain/mechanoelectrical feedback) (PubMed 36645685; PubMed 23465226) - Mechanical compression of the right ventricle/RVOT (mediastinal tumors, pectus excavatum — PMC 2021) - Myocardial ischemia or coronary vasospasm - Myocarditis/pericarditis, and infective processes such as empyema (PMC 2025) - Poor ECG lead placement/filter artifact (a technical, not physiologic, phenocopy)

This distinction (phenocopy vs. true congenital BrS) is the basis for the differential-diagnosis addition just made to the Brugada_Syndrome.yaml entry in this repository's working branch.

5.3 Infectious Agents

No infectious agent is causal for true BrS; infection acts only indirectly via fever as a trigger, or via phenocopy mechanisms (myocarditis, sepsis-associated electrolyte/metabolic derangement).

6. Mechanism / Pathophysiology

Causal chain (numbered, from initiating lesion to clinical manifestation)

A germline SCN5A (or, less commonly, another ion-channel/channel-regulatory gene) loss-of-function variant reduces functional Nav1.5 channel density or gating efficiency at the cardiomyocyte membrane, via impaired trafficking, accelerated inactivation, or reduced conductance.
This reduces peak inward sodium current (INa), most prominently in the right ventricular epicardium and RVOT, a region with intrinsically lower INa density and higher transient outward potassium current (Ito) density than the endocardium or left ventricle ("interventricular differences in sodium current" — PMC 2018).
Reduced INa, combined with relatively unopposed Ito-mediated phase-1 repolarization, causes loss of the action potential (AP) "dome" in a subpopulation of RVOT epicardial cells — this occurs heterogeneously, not uniformly, across the epicardial surface.
Heterogeneous dome loss produces marked transmural and epicardial dispersion of repolarization between adjacent sites that retain versus lose the AP dome (the "repolarization hypothesis," now the better-supported of the two classical mechanistic hypotheses — Cardiovascular Research review; JSR literature review 2024).
The voltage gradient between dome-maintaining and dome-losing regions drives electrotonic current flow ("current-load mismatch"), which manifests on the surface ECG as the coved ST-segment elevation in V1–V3 (type 1 Brugada pattern) — this is the mechanistic substrate for the diagnostic ECG sign itself.
Under further destabilizing conditions (fever, sodium-channel-blocking drugs, vagotonic bradycardia), the dome can propagate from a site where it is maintained into an adjacent site where it has been lost, generating a local re-excitation event via phase 2 reentry (Yan and Antzelevitch, 1999) — a closely coupled extrasystole arising from the epicardial dispersion substrate (PMC — Basis for Tissue-Level Phase-2 Reentry).
When three functionally distinct regions coexist in 2D/3D myocardial tissue (a region of delayed dome, a region of lost dome, and normal epicardium), the phase-2-reentrant extrasystole can degenerate into sustained reentrant circuits, producing polymorphic ventricular tachycardia that can deteriorate into ventricular fibrillation.
VF causes hemodynamic collapse and, if untreated, sudden cardiac death — the terminal clinical manifestation of the pathway; events cluster during sleep/vagal-predominant states because vagotonia further reduces INa/ICa,L balance and favors dome loss.

Branch — the depolarization/structural hypothesis (partially supported, competing/complementary): In parallel, an alternative or contributory mechanism proposes that conduction delay in the RVOT — attributable to region-specific myocardial fibrosis and reduced connexin-43 gap-junction density, sometimes with abnormal neural crest cell migration during development — produces fractionated, delayed local activation that itself generates the ST-elevation pattern and arrhythmic substrate independent of, or in addition to, dome-loss repolarization abnormalities (Cardiovascular Research, Amsterdam UMC; ScienceDirect 2010). Current consensus (2024 literature) leans toward the repolarization hypothesis as the predominant/best-experimentally-supported mechanism, based on genetically engineered experimental models reproducing the phenotype, while acknowledging the depolarization/current-load-mismatch and structural (fibrosis/connexin) contributions are not mutually exclusive and likely coexist to varying degrees across patients ("depolarization disorder, repolarization disorder, or more?" — Oxford Academic Cardiovascular Research).

Ajmaline's mechanism (relevant to diagnostic provocation and disease modeling): Beyond pure INa blockade, ajmaline also modulates potassium and calcium currents and mitochondrial/metabolic pathways; combined sodium- and calcium-current blockade in experimental models reproduces loss of the epicardial AP dome, ST elevation, phase 2 reentry, and spontaneous polymorphic VT/VF — an effect that can be normalized by 4-aminopyridine (an Ito blocker), directly implicating Ito in the repolarization mechanism (Frontiers in Cardiovascular Medicine 2021).

Molecular/cellular detail relevant to curation

Molecular pathway/GO terms: cardiac muscle cell action potential (GO:0086001); regulation of cardiac muscle cell membrane repolarization; sodium ion transmembrane transport (GO:0035725); ventricular cardiac muscle cell action potential (GO:0086005).
Protein dysfunction: Nav1.5 (UniProt Q14524) misfolding/trafficking defect or altered gating kinetics; a subset of variants are dominant-negative, reducing wild-type channel surface expression via heteromultimerization.
Cell types (CL terms): cardiac ventricular epicardial myocyte (relevant CL terms for right ventricular/RVOT cardiomyocyte); Purkinje fiber cells have also been implicated as an arrhythmogenic trigger source in some substrate-mapping studies.
Tissue damage/structural correlate: Epicardial mapping studies (BRAVO, UNCOVER(BrS)) directly visualize a fibrotic, low-voltage, fractionated-electrogram arrhythmogenic substrate localized to the anterior RVOT epicardium in symptomatic patients — the direct anatomic target of catheter ablation therapy (Heart Rhythm 2016).
Single-cell/omics: No large-scale single-cell transcriptomic atlas specific to human BrS myocardium was identified in this search; most molecular profiling data derive from iPSC-CM electrophysiology and heterologous expression systems rather than patient-tissue omics.

7. Anatomical Structures Affected

Organ level: Heart — primarily right ventricle, specifically the right ventricular outflow tract (RVOT) epicardium; this is the near-universal localization of both the ECG abnormality and the ablatable arrhythmogenic substrate.
System: Cardiovascular system.
Tissue/cell level: Ventricular epicardial myocardium (RVOT); Purkinje conduction system component in some substrate models.
Subcellular level: Plasma membrane (Nav1.5 channel localization, particularly lateral/T-tubule membrane subdomains — a 2020 study found specific decrease of Na+ channel expression on the lateral membrane of cardiomyocytes causes fatal arrhythmias in BrS, PMC 2020).
Localization/laterality: Right-sided/RVOT predominant — the electrical and structural abnormality is not diffusely biventricular, a key anatomic feature distinguishing it from most cardiomyopathies. UBERON: right cardiac ventricle; cardiac outflow tract.

8. Temporal Development

Onset: Typically adult-onset clinically (mean age at first arrhythmic event roughly 40 years), though the underlying channelopathy is congenital/present from birth; pediatric presentation occurs, usually fever-triggered, and neonatal/infant presentations are described but less common.
Onset pattern: Episodic/paroxysmal — clinical events (syncope, VF) are discrete, unpredictable episodes rather than a continuous progressive process.
Course: The ECG phenotype itself can be dynamic/concealed, fluctuating between normal, type 2/3, and type 1 patterns depending on autonomic tone, temperature, and drug exposure — this "concealed" nature complicates diagnosis and longitudinal risk assessment.
Progression: Not a degenerative or progressive structural disease in the classic sense (no progressive myocardial loss/scarring analogous to cardiomyopathies), though the epicardial fibrotic substrate identified on mapping may itself be age- or disease-duration related in some patients.
Critical periods: Febrile illness (especially in childhood), and periods of high vagal tone (sleep, rest, post-prandial) represent windows of heightened arrhythmic vulnerability.

9. Inheritance and Population Genetics

9.1 Epidemiology

ECG pattern prevalence: ~0.12–0.8% of the general population shows a Brugada-type ECG pattern (mostly non-diagnostic type 2/3) (search synthesis).
Syndrome prevalence: Commonly cited as ~1:2,000 to 1:5,000, with regional variation.
A 2024 Mayo Clinic 30-year retrospective of 5,381,186 ECGs from 2,304,809 patients found 150 patients with at least one ECG showing a type 1 Brugada pattern — of these, 76.0% met BrS criteria, 62.0% were spontaneous, 18.7% fever-induced, and 10.7% drug-induced (Mayo Clinic study, 2024).
A 2024 community-based ECG screening study from Kerala, South India found overall Brugada-pattern prevalence of 1.06% (0.04% type I, 1.01% type II/III) (doaj.org, Indian Heart Journal 2024).
Higher background prevalence is reported in Southeast Asia (Thailand, Philippines, Japan), historically overlapping with the sudden unexplained nocturnal death syndrome (SUNDS) literature; a 2023 study attributes part of Thailand's elevated prevalence to a population-enriched SCN5A regulatory (enhancer) variant (medRxiv 2023).

9.2 Inheritance Pattern

Autosomal dominant in the majority of monogenic (SCN5A-positive) cases; the exception is KCNE5-related BrS, inherited in an X-linked manner (search synthesis of GeneReviews content).
Mendelian (autosomal dominant) transmission is detectable in fewer than 25% of all clinically confirmed cases — the majority of cases either lack an identifiable monogenic cause or reflect a more complex, partly polygenic architecture (the SCN5A-SCN10A-HEY2 common-variant burden plus the broader 2022 GWAS 12-locus signal) (Annual Review of Genomics and Human Genetics summary).
Penetrance: Reduced and age- and sex-dependent; even within SCN5A-positive families, many mutation carriers remain asymptomatic throughout life, and expressivity is highly variable — "reduced penetrance and variable expressivity are hallmarks of Brugada syndrome."
Sex ratio: ~8–10:1 male predominance in symptomatic disease expression, despite equal transmission of the causal variant to both sexes.
Founder effects: Documented in specific populations (e.g., the Thai SCN5A enhancer variant).

9.3 Population Demographics

Higher prevalence/clinical recognition in East and Southeast Asian populations relative to European-ancestry populations.
Predominantly diagnosed in young to middle-aged males (peak clinical presentation 30s–40s).
Family/cascade screening is standard once a proband is identified, given autosomal dominant transmission and the value of identifying at-risk relatives before a sentinel arrhythmic event.

10. Diagnostics

10.1 Diagnostic ECG Criteria

Type 1 Brugada pattern — coved ST elevation ≥2 mm in ≥1 of V1–V2 (standard or high intercostal-space lead placement), spontaneously or after provocation — is the only ECG pattern considered diagnostic.
Pharmacologic provocation testing: Used when resting ECG shows a non-diagnostic (type 2/3, saddleback) pattern in a patient with clinical suspicion. Intravenous ajmaline is the preferred agent internationally, though its limited availability (particularly in the US) has driven increased use of oral or IV flecainide; procainamide and pilsicainide are also used (search synthesis). A 2023 diagnostic refinement — the r′-wave algorithm — was proposed to help predict a positive sodium-channel-blocker provocation test result (PMC 2023).
Fever provocation: A spontaneous or fever-induced type 1 pattern is itself diagnostic; a 12-lead ECG is recommended during febrile episodes in patients from high-risk families or with a suggestive history. A 2025 MDPI paper specifically examined type 1 Brugada pattern triggered by low-grade fever and its diagnostic/risk-stratification implications (MDPI IJMS 2025; PubMed 42123485).

10.2 Genetic Testing

Single-gene (SCN5A) or targeted arrhythmia/channelopathy gene panel testing is recommended following a clinical BrS diagnosis, primarily to enable cascade family screening.
Given only ~20–25% diagnostic yield for SCN5A and the now-limited actionable-gene list post-ClinGen reappraisal, a negative genetic test does not exclude BrS, and genetic results should not independently drive risk stratification or ICD decisions.
Whole-exome/genome sequencing is used mainly in research or when panel testing is non-diagnostic in a strongly phenotype-positive family.

10.3 Electrophysiology Study / Risk Stratification Testing

Programmed ventricular stimulation (PVS): Historically used for risk stratification; a pooled analysis found induced arrhythmia was associated with cardiac events during follow-up (HR 2.66), greatest with single/double extrastimuli (PubMed 26797467). However, more recent literature (2024–2025) questions its predictive value in specific subgroups — PVS did not predict cardiac events in elderly BrS patients in a large Japanese cohort (PMC 2025), and current guidelines do not support PVS specifically in drug-induced type 1 BrS, where SCD risk stratification remains especially challenging. A commentary explicitly asks whether PVS risk prediction is "closing time" (Revista Española de Cardiología 2021).
Non-invasive ECG risk markers (2024–2025 focus): β-angle, fragmented QRS, S wave in lead I, early repolarization pattern, the aVR sign, and quantified transmural dispersion of repolarization have shown predictive value for arrhythmic events and are increasingly emphasized as adjuncts/alternatives to invasive PVS (Frontiers in Cardiovascular Medicine 2025 mini-review; Journal of Interventional Cardiac Electrophysiology 2025).

10.4 Differential Diagnosis

Distinguishing true congenital BrS from Brugada phenocopy (see §5.2) is a core diagnostic step — phenocopies are reversible and resolve with treatment of the underlying cause (correcting electrolytes, treating PE, draining an effusion/empyema, resolving ischemia), whereas true BrS is a lifelong genetic predisposition requiring ongoing risk management.

11. Outcome/Prognosis

BrS is a recognized major cause of sudden cardiac death in patients under 50 years old, particularly in populations without coronary artery disease.
Overall risk stratification remains a major unmet clinical challenge — the majority of BrS carriers (especially those identified through family screening, without prior symptoms) have a relatively benign course, while a minority experience life-threatening arrhythmic events, and current tools imperfectly separate these groups (Frontiers in Cardiovascular Medicine 2025).
Established higher-risk features: spontaneous (vs. drug-induced) type 1 pattern, prior aborted cardiac arrest or documented VF, unexplained syncope, family history of sudden death, male sex, and (per 2024 JACC data) certain nonmodifiable risk factors shown to independently predict outcomes (JACC 2024; JACC 2024 — Risk Stratification: Selecting the Population of Interest).
ICD complication burden: A major driver of current management controversy — ICDs are highly effective at preventing SCD but are associated with substantial complication rates (inappropriate shocks, lead failure, infection) in this typically younger patient population, motivating research into risk-stratified, ICD-sparing strategies (quinidine, catheter ablation).

12. Treatment

12.1 Device Therapy

Implantable cardioverter-defibrillator (ICD) remains the only therapy with proven mortality benefit in high-risk BrS patients (recurrent VF, aborted SCD, high-risk PVS/ECG markers). NCIT: consider NCIT:C15329 (Surgical Procedure) for implantation, with therapeutic_modality: DEVICE.

12.2 Pharmacotherapy

Quinidine (Class IA antiarrhythmic, Ito blocker) — Class IIa indication for BrS patients with electrical storm or recurrent appropriate ICD shocks; shown to significantly reduce shock burden in patients with malignant ventricular arrhythmia episodes (JACC 2016; Circulation). CHEBI: quinidine (CHEBI:28593).
Isoproterenol (IV infusion) — used acutely for electrical storm suppression by increasing ICa,L and restoring the epicardial AP dome.
Antipyretics — prompt fever treatment is considered one of the most effective, low-risk preventive interventions in BrS patients (BrugadaDrugs.org).
Drugs to avoid (comprehensively catalogued at BrugadaDrugs.org, a physician-curated reference): sodium-channel blockers including ajmaline, flecainide, propafenone, procainamide, pilsicainide, allapinin, ethacizin; certain tricyclic antidepressants; cocaine; excessive alcohol; and, per case reports, agents such as lacosamide in the context of critical illness (Medscape treatment overview; PMC 2021 lacosamide case).

12.3 Catheter Ablation (Major Area of 2023–2025 Development)

Epicardial substrate ablation targeting the anterior RVOT arrhythmogenic substrate has emerged as an important adjunct/alternative therapy, particularly for ICD-refractory or ICD-refusing patients:

BRAVO Registry (Brugada Ablation of VF Substrate Ongoing Multicenter Registry, Circulation 2023): catheter ablation of the epicardial substrate is safe and effective at preventing VF recurrence in high-risk BrS patients; VF burden fell from 1.1 ± 2.1 episodes/month pre-ablation to 0.003 ± 0.14 episodes/month post-ablation (p < 0.0001) (Circulation 2023).
A 2024 study of patients with symptomatic BrS who declined ICD implantation found catheter ablation (performed in 66.7% of the cohort) associated with significantly better arrhythmic outcomes than ICD alone (primary outcome 5.6% vs. 54.5%, log-rank p = 0.012) over a median 46.2-month follow-up (EP Europace 2024).
UNCOVER(BrS) study (2024) demonstrated feasibility and preliminary safety of epicardial substrate ablation via a hybrid mini-thoracotomy approach, with no symptomatic arrhythmic recurrences at 12-month follow-up (PMC 2024).
A 2023 systematic review/meta-analysis discusses the "future direction" of substrate-based ablation across inherited primary arrhythmia syndromes including BrS (Journal of Arrhythmia 2023).
Ongoing debate: whether RVOT epicardial substrate ablation should become standard of care in high-risk BrS remains actively discussed in the literature (PMC commentary).

12.4 Genetic/Precision Approaches

A registered clinical trial (NCT07039123) is evaluating a polygenic risk score to optimize primary prevention (ICD candidacy) in intermediate-risk BrS populations — an active translational research direction bridging the 2022 GWAS findings into clinical decision-making (ClinicalTrials.gov).

13. Prevention

Primary prevention: Avoidance of known pharmacologic and physiologic triggers (sodium-channel-blocking drugs, cocaine, excessive alcohol); prompt antipyretic treatment of fever.
Secondary prevention: Cascade genetic and clinical (ECG ± provocation) screening of first-degree relatives of a BrS proband, given autosomal-dominant transmission.
Genetic counseling: Recommended for all confirmed BrS families given the dominant inheritance pattern, reduced penetrance, and variable expressivity — counseling should explicitly address that a child's risk of inheriting a familial pathogenic variant may functionally translate to less than full disease expression due to penetrance/environmental modifiers.
Risk stratification-guided prophylaxis: ICD implantation in confirmed high-risk patients (prior VF/aborted SCD); quinidine as pharmacologic prophylaxis in select intermediate/high-risk patients or those with recurrent ICD shocks.
Public health / point-of-care: Physician and patient education resources (e.g., BrugadaDrugs.org) function as a de facto prophylactic tool by preventing inadvertent prescription of triggering medications.

14. Other Species / Comparative Biology

No robust naturally occurring veterinary BrS phenotype analogous to the human disease is well established in the literature surveyed; most cross-species data come from engineered models rather than natural companion-animal or wildlife disease. Orthologous Scn5a is well conserved across mammals (mouse, canine, porcine), enabling the modeling described below, but naturally occurring inherited canine/feline Brugada-like disease was not identified in this search.

15. Model Organisms

Murine (mouse) models: Scn5a knockout or knock-in of specific human BrS-associated point mutations are used to replicate a generic or family-specific BrS phenotype; heterozygous Scn5a-null mice reproduce conduction slowing and arrhythmia susceptibility, though homozygous knockout is embryonic lethal (search synthesis).
Zebrafish (Danio rerio) models: Increasingly used given cardiac electrophysiological similarities to humans; valuable both for gene-editing (CRISPR) disease modeling and for chemical/drug screening in BrS (Reviews in Cardiovascular Medicine 2024; PMC 2024).
Human iPSC-derived cardiomyocytes (iPSC-CMs): Considered the best current in vitro model for complex inherited arrhythmia syndromes like BrS because they retain the patient's genetic background; used to study Nav1.5 trafficking/gating defects, drug responses, and to test candidate therapeutics (IJMS 2021, PMC; PubMed 33802229).
Heterologous expression systems: HEK293 cells transfected with wild-type or mutant SCN5A/Nav1.5 constructs remain the primary system for detailed biophysical/patch-clamp characterization of variant functional consequences (used to classify VUS as LOF, GOF, or neutral).
Model limitations: Species-specific differences in cardiac electrophysiology (e.g., differing ion channel current densities and repolarization reserve between rodents and humans) limit direct translational extrapolation from murine models; iPSC-CMs, while patient-specific, retain relative electrophysiological immaturity (fetal-like phenotype) compared to adult human cardiomyocytes, a limitation widely acknowledged in the iPSC-CM literature.

Summary of Key Ontology Term Suggestions for Curation

Table (click to expand)

Domain	Suggested term
Disease	MONDO:0015263 (Brugada syndrome)
Causal gene	hgnc:10593 (SCN5A)
Modifier/susceptibility loci	SCN10A (hgnc:10582), HEY2 (hgnc:16116)
Phenotype	Syncope (HP:0001279); Ventricular fibrillation (HP:0001663); Sudden death (search HPO for exact leaf term)
Molecular function	protein-coding voltage-gated sodium channel activity (GO:0005248)
Biological process	cardiac muscle cell action potential (GO:0086001); ventricular cardiac muscle cell action potential (GO:0086005)
Cell type	cardiac ventricular myocyte (search CL for RV/epicardial specificity)
Anatomy	right cardiac ventricle / right ventricular outflow tract (UBERON)
Chemical/drug	quinidine (CHEBI:28593); flecainide, ajmaline (as trigger/provocation agents)
Treatment	NCIT:C15986 (Pharmacotherapy) + therapeutic_agent quinidine; NCIT surgical/device term for ICD; catheter ablation term

Sources

Reference Validation

Checked with linkml-reference-validator 0.3.0rc3.

Table (click to expand)

Outcome	Count
References checked	37
Resolved	37
Unresolved (possible confabulation)	0
Unverifiable	0
Quoted claims checked	2
Quoted claims found in source	0
Quoted claims not found in source	2
References weighed for topical relevance	37
On topic	26
Off topic	0

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

Every one of these was searched against an abstract alone, with no full text retrieved - marked abstract only below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

PMID:42123485 (abstract only): "fever worsens sodium channel dysfunction by further reducing conductance"
closest text in source: "Fever worsens sodium channel dysfunction, as elevated temperature further reduces their conductance"
PMID:42123485 (abstract only): "12-lead ECG is strongly recommended even in a low-grade fever state in patients belonging to a high-risk group"
closest text in source: "During the patient's subfebrile episodes, 12-lead ECG recordings revealed ST-segment elevations in leads V1-V3"

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Table (click to expand)

Outcome	Count
Terms checked	15
Resolved	13
Unresolved (possible confabulation)	0
Obsolete	0
Unverifiable	2
Terms whose name was checked	7
Terms named correctly	5
Terms named as a different term	0
Terms whose name is worth a second look	2

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

GO:0086001 (2 mentions) - the report calls it "Molecular pathway/GO terms: cardiac muscle cell action potential"; GO calls it cardiac muscle cell action potential**
GO:0005248 (1 mention) - the report calls it "protein-coding voltage-gated sodium channel activity"; GO calls it voltage-gated sodium channel activity

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA.

13 of 15 terms resolved to a current term; the rest could not be looked up either way.